Promis Neurosciences Inc. insider trading
Every open-market purchase and sale by Promis Neurosciences Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Promis Neurosciences Inc.’s insiders pay?
From August 18, 2022 to August 7, 2026, 8 insiders reported 13 open-market purchases and 0 sales not made under a pre-set plan in Promis Neurosciences Inc. Twelve months after each purchase was reported, the shares were −72.6% against the S&P 500 on average (median −72.6%), over 1 purchase with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on August 19, 2022 into $709 by November 2, 2026, −46.9% a year. It held shares 41% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $13,127 (+6.7% a year), and held throughout $18,952 (+16.5%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Kirwin Patrick D. | Director | 4 | −72.6% (1) | 0% | 0 | — | April 23, 2026 |
| Kaplan Johanne | Chief Development Officer | 2 | — | — | 0 | — | August 7, 2026 |
| Williams Eugene | Director | 2 | — | — | 0 | — | March 6, 2026 |
| Cashman Neil | Chief Scientific Officer | 1 | — | — | 0 | — | February 12, 2025 |
| Gordon Michael S | 10% owner | 1 | — | — | 0 | — | September 18, 2024 |
| Milbury Max A. | Other | 1 | — | — | 0 | — | October 6, 2025 |
| Shafmaster Madge K. | Director | 1 | — | — | 0 | — | September 24, 2024 |
| Yu Fan | Director | 1 | — | — | 0 | — | February 5, 2026 |
When several insiders traded Promis Neurosciences Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Promis Neurosciences Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −54.1% against the index. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| February 27, 2026 | 2 buying | −64.6% | −54.1% | not yet |